First report of a clinical and radiologic response to vorasidenib in a patient with isocitrate dehydrogenase-mutant brainstem astrocytoma
{{output}}
Background: IDH (isocitrate dehydrogenase)-mutant gliomas of the brainstem are exceedingly rare. In the INDIGO trial, patients with brainstem gliomas were excluded, thus, no data exists on the use of vorasidenib in this group. ... ...